ClinicalTrials.gg
CompletedNCT02178098Updated Apr 4, 2023Results posted

Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension

A Phase 2 interventional study of ETC-1002 and Placebo in Hypercholesterolemia and Hypertension, sponsored by Esperion Therapeutics, Inc.. Completed at 43 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-04-04.

Sponsored by Esperion Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.

Enrollment
9th of 21
143 · median 126
Started
2014
with 1 other
Phase 2
10 of 21
none open now
Registered
5th of 21
by date
Lead sponsor
15 of 21
Esperion Therapeutics, Inc.

Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 9th largest by enrollment, is one of 2 that started in 2014, is one of 10 in phase 2, and was the 5th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About bempedoic acid

bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing bempedoic acid in Hypercholesterolemia, or all of them as a file.
02

Study summary

This Phase 2 study will assess the efficacy and safety of ETC-1002 monotherapy versus placebo in participants with hypercholesterolemia and hypertension.

03

Conditions studied

  • Hypercholesterolemia
  • Hypertension

Keywords

  • LDL
  • Cholesterol
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mean 24-hour ambulatory SBP greater than or equal to 130 mmHg
  • or- Mean 24-hour ambulatory DBP greater than or equal to 80 mmHg
  • Fasting LDL-C between 100 and 220 mg/dL
  • Fasting triglycerides less than 400 mg/dL
  • (BMI) between 18 and 45 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Known or suspected secondary hypertension or history of malignant hypertension
  • Taking more than two anti-hypertension medications at the first visit
  • History or current cardiovascular disease
  • History or current type 1 diabetes or type 2 diabetes
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    ETC-1002

    ETC-1002 180 mg/day

    Drug: ETC-1002

  • Placebo comparator
    Placebo

    Placebo control

    Drug: Placebo

Interventions

  • ETC-1002 capsules taken once daily

  • DrugPlacebo

    Placebo capsules taken once daily

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) to Week 6

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Percent change from Baseline in LDL-C was analyzed using an analysis of covariance (ANCOVA) model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value. For the Week 6 endpoint, missing values at Week 6 were imputed using the last observation carried forward (LOCF) procedure, with only post-Baseline values carried forward. Modified Intent-to-Treat (mITT) Population is defined as all randomized participants who received at least 1 dose of study drug, had a Baseline assessment, and had at least 1 post-Baseline assessment, excluding any assessment taken more than 2 days after a dose of study drug

    Time frame: Baseline; 6 weeks

Secondary outcomes

  1. Change From Baseline in Mean 24-hour Systolic Blood Pressure (SBP) to Week 6

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.

    Time frame: Baseline; 6 weeks

  2. Change From Baseline in 24-hour Mean Diastolic Blood Pressure (DBP) to Week 6

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.

    Time frame: Baseline; 6 weeks

  3. Change From Baseline in Mean Daytime SBP to Week 6

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Daytime measurements were defined as those taken from 7 AM to 10 PM (\>7 AM and ≤10 PM). The Week 6 endpoint was the last available post-Baseline value.

    Time frame: Baseline; 6 weeks

  4. Change From Baseline in Mean Daytime DBP to Week 6

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Daytime measurements were defined as those taken from 7 AM to 10 PM (\>7 AM and ≤10 PM). The Week 6 endpoint was the last available post-Baseline value.

    Time frame: Baseline; 6 weeks

  5. Change From Baseline in Mean Nighttime SBP to Week 6

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Nighttime measurements were defined as those taken from 10 PM to 7 AM (\>10 PM and ≤7 AM). The Week 6 endpoint was the last available post-Baseline value.

    Time frame: Baseline; 6 weeks

  6. Change From Baseline in Mean Nighttime DBP to Week 6

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Nighttime measurements were defined as those taken from 10 PM to 7 AM (\>10 PM and ≤7 AM). The Week 6 endpoint was the last available post-Baseline value.

    Time frame: Baseline; 6 weeks

  7. Change From Baseline in Sitting Cuff SBP to Week 6

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the mean of the values from Weeks -1 and 0. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Three BP measurements were collected at least 3 minutes apart, and the mean of the second and third measurements was calculated and used for summary and analysis. The Week 6 endpoint was the last available post-Baseline value.

    Time frame: Baseline: 6 weeks

  8. Change From Baseline in Sitting Cuff DBP to Week 6

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the mean of the values from Weeks -1 and 0. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Three BP measurements were collected at least 3 minutes apart, and the mean of the second and third measurements was calculated and used for summary and analysis. The Week 6 endpoint was the last available post-Baseline value.

    Time frame: Baseline; 6 weeks

  9. Percent Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) to Week 6

    A non-parametric analysis was performed for hsCRP parameters. Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the last value prior to the first dose of study medication. If hsCRP was \<0.2, 0.1 was imputed for analysis. The Week 6 endpoint was the last available post-Baseline value.

    Time frame: Baseline; 6 weeks

  10. Percent Change From Baseline in Total Cholesterol to Week 6

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Change from Baseline was calculated using an ANCOVA model with terms for treatment and statin intolerance, and value as a covariate. The Week 6 endpoint was the last available post-Baseline value.

    Time frame: Baseline; 6 weeks

  11. Percent Change From Baseline in Apolipoprotein B (ApoB) to Week 6

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Change from Baseline was calculated using an ANCOVA model with terms for treatment and statin intolerance, and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.

    Time frame: Baseline; 6 weeks

  12. Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) to Week 6

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.

    Time frame: Baseline; 6 weeks

  13. Percent Change From Baseline in Triglycerides (TG) to Week 6

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. The Week 6 endpoint was the last available post-Baseline value. Data was analyzed using non-parametric analysis.

    Time frame: Baseline; 6 weeks

  14. Percent Change From Baseline in HDL-C to Week 6

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Change from Baseline was calculated using an ANCOVA model with terms for treatment and statin intolerance, and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.

    Time frame: Baseline; 6 weeks

  15. Percent Change From Baseline in Free Fatty Acids (FFA) to Week 6

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. The Week 6 endpoint was the last available post-Baseline value.

    Time frame: Baseline; 6 weeks

  16. Change From Baseline in Body Weight to Week 6

    Baseline was defined as the mean of the values from Week -1 and Week 0. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline; 6 weeks

  17. Plasma Trough Concentrations of ETC-1002 and Metabolite ESP15228

    Plasma trough concentration is defined as the lowest concentration reached before the next dose is administered.

    Time frame: Week 2, Week 4 and Week 6

07

Results

Posted Apr 4, 2023

Participant flow

Participant flow — Overall Study
MilestonePlaceboETC-1002 180 mg
Started7271
Completed6759
Not completed512
Withdrew: Withdrawal by subject06
Withdrew: Adverse event12
Withdrew: Protocol violation11
Withdrew: Lost to follow-up01
Withdrew: Sponsor request10
Withdrew: Other22

Outcome measures

PrimaryPercent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) to Week 6

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Percent change from Baseline in LDL-C was analyzed using an analysis of covariance (ANCOVA) model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value. For the Week 6 endpoint, missing values at Week 6 were imputed using the last observation carried forward (LOCF) procedure, with only post-Baseline values carried forward. Modified Intent-to-Treat (mITT) Population is defined as all randomized participants who received at least 1 dose of study drug, had a Baseline assessment, and had at least 1 post-Baseline assessment, excluding any assessment taken more than 2 days after a dose of study drug

Time frame:
Baseline; 6 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) to Week 6
Percent ChangePlaceboETC-1002 180 mg
Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) to Week 63.16 ± 2.133-21.08 ± 2.196
Statistical analysis
  • Placebo vs ETC-1002 180 mg · ANCOVA · p = <0.0001 · Least squares mean difference: -24.24 · 95% CI -30.33 to -18.15The least squares mean difference was calculated as the value for the ETC-1002 180 mg arm minus the value for the placebo arm.
SecondaryChange From Baseline in Mean 24-hour Systolic Blood Pressure (SBP) to Week 6

Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.

Time frame:
Baseline; 6 weeks
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline in Mean 24-hour Systolic Blood Pressure (SBP) to Week 6
millimeters of mercury (mmHg)PlaceboETC-1002 180 mg
Change From Baseline in Mean 24-hour Systolic Blood Pressure (SBP) to Week 6-0.64 ± 1.045-2.28 ± 1.085
Statistical analysis
  • Placebo vs ETC-1002 180 mg · ANCOVA · p = 0.2808 · Least squares mean difference: -1.64 · 95% CI -4.62 to 1.35The least squares mean difference was calculated as the value for the ETC-1002 180 mg arm minus the value for the placebo arm.
SecondaryChange From Baseline in 24-hour Mean Diastolic Blood Pressure (DBP) to Week 6

Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.

Time frame:
Baseline; 6 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in 24-hour Mean Diastolic Blood Pressure (DBP) to Week 6
mmHgPlaceboETC-1002 180 mg
Change From Baseline in 24-hour Mean Diastolic Blood Pressure (DBP) to Week 6-0.05 ± 0.760-1.10 ± 0.790
Statistical analysis
  • Placebo vs ETC-1002 180 mg · ANCOVA · p = 0.3461 · Least squares mean difference: -1.05 · 95% CI -3.25 to 1.15The least squares mean difference was calculated as the value for the ETC-1002 180 mg arm minus the value for the placebo arm.
SecondaryChange From Baseline in Mean Daytime SBP to Week 6

Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Daytime measurements were defined as those taken from 7 AM to 10 PM (\>7 AM and ≤10 PM). The Week 6 endpoint was the last available post-Baseline value.

Time frame:
Baseline; 6 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Daytime SBP to Week 6
mmHgPlaceboETC-1002 180 mg
Change From Baseline in Mean Daytime SBP to Week 6-0.35 ± 1.198-2.66 ± 1.245
Statistical analysis
  • Placebo vs ETC-1002 180 mg · ANCOVA · p = 0.1852 · Least squares mean difference: -2.31 · 95% CI -5.74 to 1.12The least squares mean difference was calculated as the value for the ETC-1002 180 mg arm minus the value for the placebo arm.
SecondaryChange From Baseline in Mean Daytime DBP to Week 6

Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Daytime measurements were defined as those taken from 7 AM to 10 PM (\>7 AM and ≤10 PM). The Week 6 endpoint was the last available post-Baseline value.

Time frame:
Baseline; 6 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Daytime DBP to Week 6
mmHgPlaceboETC-1002 180 mg
Change From Baseline in Mean Daytime DBP to Week 6-0.01 ± 0.856-1.47 ± 0.890
Statistical analysis
  • Placebo vs ETC-1002 180 mg · ANCOVA · p = 0.2481 · Least squares mean difference: -1.45 · 95% CI -3.93 to 1.03The least squares mean difference was calculated as the value for the ETC-1002 180 mg arm minus the value for the placebo arm.
SecondaryChange From Baseline in Mean Nighttime SBP to Week 6

Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Nighttime measurements were defined as those taken from 10 PM to 7 AM (\>10 PM and ≤7 AM). The Week 6 endpoint was the last available post-Baseline value.

Time frame:
Baseline; 6 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Nighttime SBP to Week 6
mmHgPlaceboETC-1002 180 mg
Change From Baseline in Mean Nighttime SBP to Week 6-1.18 ± 1.167-1.57 ± 1.212
Statistical analysis
  • Placebo vs ETC-1002 180 mg · ANCOVA · p = 0.8181 · Least squares mean difference: -0.39 · 95% CI -3.72 to 2.94The least squares mean difference was calculated as the value for the ETC-1002 180 mg arm minus the value for the placebo arm.
SecondaryChange From Baseline in Mean Nighttime DBP to Week 6

Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Nighttime measurements were defined as those taken from 10 PM to 7 AM (\>10 PM and ≤7 AM). The Week 6 endpoint was the last available post-Baseline value.

Time frame:
Baseline; 6 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Nighttime DBP to Week 6
mmHgPlaceboETC-1002 180 mg
Change From Baseline in Mean Nighttime DBP to Week 6-0.52 ± 0.879-0.33 ± 0.913
Statistical analysis
  • Placebo vs ETC-1002 180 mg · ANCOVA · p = 0.8817 · Least squares mean difference: 0.19 · 95% CI -2.33 to 2.71The least squares mean difference was calculated as the value for the ETC-1002 180 mg arm minus the value for the placebo arm.
SecondaryChange From Baseline in Sitting Cuff SBP to Week 6

Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the mean of the values from Weeks -1 and 0. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Three BP measurements were collected at least 3 minutes apart, and the mean of the second and third measurements was calculated and used for summary and analysis. The Week 6 endpoint was the last available post-Baseline value.

Time frame:
Baseline: 6 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Cuff SBP to Week 6
mmHgPlaceboETC-1002 180 mg
Change From Baseline in Sitting Cuff SBP to Week 6-4.98 ± 1.274-3.45 ± 1.311
Statistical analysis
  • Placebo vs ETC-1002 180 mg · ANCOVA · p = 0.4040 · Least squares mean difference: 1.53 · 95% CI -2.09 to 5.15The least squares mean difference was calculated as the value for the ETC-1002 180 mg arm minus the value for the placebo arm.
SecondaryChange From Baseline in Sitting Cuff DBP to Week 6

Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Baseline was defined as the mean of the values from Weeks -1 and 0. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. Three BP measurements were collected at least 3 minutes apart, and the mean of the second and third measurements was calculated and used for summary and analysis. The Week 6 endpoint was the last available post-Baseline value.

Time frame:
Baseline; 6 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in Sitting Cuff DBP to Week 6
mmHgPlaceboETC-1002 180 mg
Change From Baseline in Sitting Cuff DBP to Week 6-3.32 ± 0.820-2.53 ± 0.844
Statistical analysis
  • Placebo vs ETC-1002 180 mg · ANCOVA · p = 0.5061 · Least squares mean difference: 0.79 · 95% CI -1.54 to 3.11The least squares mean difference was calculated as the value for the ETC-1002 180 mg arm minus the value for the placebo arm.
SecondaryPercent Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) to Week 6

A non-parametric analysis was performed for hsCRP parameters. Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the last value prior to the first dose of study medication. If hsCRP was \<0.2, 0.1 was imputed for analysis. The Week 6 endpoint was the last available post-Baseline value.

Time frame:
Baseline; 6 weeks
Reported as:
Median · Percent Change
Percent Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) to Week 6
Percent ChangePlaceboETC-1002 180 mg
Percent Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) to Week 619.61 (-16.67 to 64.29)-25.00 (-50.85 to 0.00)
Statistical analysis
  • Placebo vs ETC-1002 180 mg · Wilcoxon Rank-Sum Test · p = <0.0001 · Median difference (final values): -43.64 · 95% CI -62.80 to -25.21The 95% confidence interval (CI) was calculated using Hodges-Lehmann analysis.
SecondaryPercent Change From Baseline in Total Cholesterol to Week 6

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Change from Baseline was calculated using an ANCOVA model with terms for treatment and statin intolerance, and value as a covariate. The Week 6 endpoint was the last available post-Baseline value.

Time frame:
Baseline; 6 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Total Cholesterol to Week 6
Percent ChangePlaceboETC-1002 180 mg
Percent Change From Baseline in Total Cholesterol to Week 62.90 ± 1.389-13.77 ± 1.430
Statistical analysis
  • Placebo vs ETC-1002 180 mg · ANCOVA · p = <0.0001 · Least squares mean difference: -16.67 · 95% CI -20.63 to -12.70The least squares mean difference was calculated as the value for the ETC-1002 180 mg arm minus the value for the placebo arm.
SecondaryPercent Change From Baseline in Apolipoprotein B (ApoB) to Week 6

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Change from Baseline was calculated using an ANCOVA model with terms for treatment and statin intolerance, and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.

Time frame:
Baseline; 6 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Apolipoprotein B (ApoB) to Week 6
Percent ChangePlaceboETC-1002 180 mg
Percent Change From Baseline in Apolipoprotein B (ApoB) to Week 64.77 ± 1.797-14.13 ± 1.911
Statistical analysis
  • Placebo vs ETC-1002 180 mg · ANCOVA · p = <0.0001 · Least squares mean difference: -18.90 · 95% CI -24.09 to -13.71The least squares mean difference was calculated as the value for the ETC-1002 180 mg arm minus the value for the placebo arm.
SecondaryPercent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) to Week 6

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the last value prior to the first dose of study medication. Change from Baseline was calculated using an ANCOVA model with a term for treatment and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.

Time frame:
Baseline; 6 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) to Week 6
Percent ChangePlaceboETC-1002 180 mg
Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) to Week 63.20 ± 1.728-15.49 ± 1.779
Statistical analysis
  • Placebo vs ETC-1002 180 mg · ANCOVA · p = <0.0001 · Least squares mean difference: -18.69 · 95% CI -23.62 to -13.77The least squares mean difference was calculated as the value for the ETC-1002 180 mg arm minus the value for the placebo arm.
SecondaryPercent Change From Baseline in Triglycerides (TG) to Week 6

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. The Week 6 endpoint was the last available post-Baseline value. Data was analyzed using non-parametric analysis.

Time frame:
Baseline; 6 weeks
Reported as:
Median · Percent Change
Percent Change From Baseline in Triglycerides (TG) to Week 6
Percent ChangePlaceboETC-1002 180 mg
Percent Change From Baseline in Triglycerides (TG) to Week 6-3.75 (-18.67 to 15.69)-0.07 (-20.63 to 36.38)
Statistical analysis
  • Placebo vs ETC-1002 180 mg · Wilcoxon Rank-Sum Test · p = 0.3689 · Median difference (final values): 5.25 · 95% CI -6.78 to 16.42The 95% CI was calculated using Hodges-Lehmann analysis.
SecondaryPercent Change From Baseline in HDL-C to Week 6

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. Change from Baseline was calculated using an ANCOVA model with terms for treatment and statin intolerance, and Baseline value as a covariate. The Week 6 endpoint was the last available post-Baseline value.

Time frame:
Baseline; 6 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in HDL-C to Week 6
Percent ChangePlaceboETC-1002 180 mg
Percent Change From Baseline in HDL-C to Week 62.42 ± 1.614-5.76 ± 1.661
Statistical analysis
  • Placebo vs ETC-1002 180 mg · ANCOVA · p = 0.0006 · Least squares mean difference: -8.18 · 95% CI -12.76 to -3.59The least squares mean difference was calculated as the value for the ETC-1002 180 mg arm minus the value for the placebo arm.
SecondaryPercent Change From Baseline in Free Fatty Acids (FFA) to Week 6

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Week 0. The Week 6 endpoint was the last available post-Baseline value.

Time frame:
Baseline; 6 weeks
Reported as:
Median · Percent Change
Percent Change From Baseline in Free Fatty Acids (FFA) to Week 6
Percent ChangePlaceboETC-1002 180 mg
Percent Change From Baseline in Free Fatty Acids (FFA) to Week 61.08 (-23.81 to 30.46)9.56 (-19.49 to 43.53)
Statistical analysis
  • Placebo vs ETC-1002 180 mg · Wilcoxon Rank-Sum Test · p = 0.3093 · Median difference (final values): 7.60 · 95% CI -8.21 to 24.02The 95% CI was calculated using Hodges-Lehmann analysis.
SecondaryChange From Baseline in Body Weight to Week 6

Baseline was defined as the mean of the values from Week -1 and Week 0. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline; 6 weeks
Reported as:
Mean · kilograms
Change From Baseline in Body Weight to Week 6
kilogramsPlaceboETC-1002 180 mg
Change From Baseline in Body Weight to Week 6-0.335 ± 1.590-0.009 ± 1.927
SecondaryPlasma Trough Concentrations of ETC-1002 and Metabolite ESP15228

Plasma trough concentration is defined as the lowest concentration reached before the next dose is administered.

Time frame:
Week 2, Week 4 and Week 6
Reported as:
Mean · nanograms per milliliter (ng/mL)
Plasma Trough Concentrations of ETC-1002 and Metabolite ESP15228
nanograms per milliliter (ng/mL)ETC-1002 180 mg
Week 2, ETC-10026666.20 ± 4777.661
Week 4, ETC-10026817.45 ± 4543.944
Week 6, ETC-10026836.36 ± 3702.241
Week 2, ESP152281219.60 ± 783.00
Week 4, ESP152281220.79 ± 674.437
Week 6, ESP152281221.32 ± 557.930

Adverse events

Collected over Up to approximately 14 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/72 (0%)2/72 (2.8%)4/72 (5.6%)
ETC-1002 180 mg0/71 (0%)4/71 (5.6%)3/71 (4.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboETC-1002 180 mg
Non-cardiac chest painGeneral disorders0/722/71
Atrial flutterCardiac disorders0/721/71
Craniocerebral injuryInjury, poisoning and procedural complications0/721/71
Acute myocardial infarctionCardiac disorders1/720/71
Sinus tachycardiaCardiac disorders1/720/71
Colon adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/720/71
Most frequent other events
Most frequent other events
EventPlaceboETC-1002 180 mg
HeadacheNervous system disorders4/723/71

Baseline characteristics

Baseline data are reported for members of the Safety Population, comprised of all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboETC-1002 180 mgTotal
Mean56.5 ± 8.2954.6 ± 8.4155.6 ± 8.38
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboETC-1002 180 mgTotal
Female352661
Male374582
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboETC-1002 180 mgTotal
Asian123
Black or African American231740
White454994
More than one race123
Unknown213
08

Study locations

43 sites
  • Birmingham, Alabama 35209, United States
  • Muscle Shoals, Alabama 35662, United States
  • Chandler, Arizona 85224, United States
  • Glendale, Arizona 85306, United States
  • Los Angeles, California 90057, United States
  • DeLand, Florida 32720, United States
  • Fort Lauderdale, Florida 33306, United States
  • Hialeah, Florida 33012, United States
  • Oviedo, Florida 32765, United States
  • Pembroke Pines, Florida 33026, United States
  • Pembroke Pines, Florida 33029, United States
  • Port Orange, Florida 32127, United States
  • Meridian, Idaho 83646, United States
  • Chicago, Illinois 60607, United States
  • Gurnee, Illinois 60031, United States
  • Indianapolis, Indiana 46260, United States
  • Paducah, Kentucky 42003, United States
  • Auburn, Maine 04210, United States
  • Olive Branch, Mississippi 38654, United States
  • Butte, Montana 59701, United States
  • Las Vegas, Nevada 89123, United States
  • Berlin, New Jersey 08009, United States
  • Endwell, New York 13760, United States
  • Wilmington, North Carolina 28401, United States
  • Cincinnati, Ohio 45219, United States
  • Cincinnati, Ohio 45245, United States
  • Cincinnati, Ohio 45246, United States
  • Lyndhurst, Ohio 44124, United States
  • Willoughby Hills, Ohio 44094, United States
  • Tulsa, Oklahoma 74136, United States
  • Eugene, Oregon 97404, United States
  • Downingtown, Pennsylvania 19335, United States
  • Site 1
    Mount Pleasant, South Carolina 29464, United States
  • Site 2
    Mount Pleasant, South Carolina 29464, United States
  • Simpsonville, South Carolina 29681, United States
  • Corpus Christi, Texas 78404, United States
  • Dallas, Texas 75230, United States
  • Dallas, Texas 75234, United States
  • Houston, Texas 77036, United States
  • Salt Lake City, Utah 84107, United States
  • Salt Lake City, Utah 84124, United States
  • Kenosha, Wisconsin 53142, United States
  • Madison, Wisconsin 53719, United States
09

References and documents

Publications

  • Ballantyne CM, Davidson MH, Macdougall DE, Bays HE, Dicarlo LA, Rosenberg NL, Margulies J, Newton RS. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013 Sep 24;62(13):1154-62. doi: 10.1016/j.jacc.2013.05.050. Epub 2013 Jun 13. PubMed 23770179 ↗
  • Gutierrez MJ, Rosenberg NL, Macdougall DE, Hanselman JC, Margulies JR, Strange P, Milad MA, McBride SJ, Newton RS. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):676-83. doi: 10.1161/ATVBAHA.113.302677. Epub 2014 Jan 2. PubMed 24385236 ↗
  • Pinkosky SL, Filippov S, Srivastava RA, Hanselman JC, Bradshaw CD, Hurley TR, Cramer CT, Spahr MA, Brant AF, Houghton JL, Baker C, Naples M, Adeli K, Newton RS. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013 Jan;54(1):134-51. doi: 10.1194/jlr.M030528. Epub 2012 Nov 1. PubMed 23118444 ↗
  • Filippov S, Pinkosky SL, Lister RJ, Pawloski C, Hanselman JC, Cramer CT, Srivastava RAK, Hurley TR, Bradshaw CD, Spahr MA, Newton RS. ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. J Lipid Res. 2013 Aug;54(8):2095-2108. doi: 10.1194/jlr.M035212. Epub 2013 May 24. PubMed 23709692 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in May 2015, 11 months.

Results were first posted in Apr 2023, 7 years 10 months after primary completion. A results delay was requested in Aug 2015.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 11 months is above that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2014
First posted
Jun 30, 2014
StartActual
Jun 16, 2014
Primary completionActual
May 22, 2015
CompletionActual
May 22, 2015
Results delay requested
Aug 13, 2015
Results first posted
Apr 4, 2023
Last update
Apr 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02178098
Collaborators
Medpace, Inc.
Responsible party
Sponsor
First posted
Jun 30, 2014
Start date
Jun 16, 2014
Primary completion
May 22, 2015
Completion
May 22, 2015
Results posted
Apr 4, 2023
Last update
Apr 4, 2023

Study contacts

Medpace Medical Monitor
study director · Medpace, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bempedoic acid

Start the discussion